Award - Development of Novel Drug Particles for Inhalational Therapy
Award Notice Posted
- Solicitation number
- HT9425-24-D-0011
- Agency
-
Defense Health Agency
Department of Defense
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HT9425-24-D-0011 Federal IDV award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Place of performance
- Frederick, Maryland 21702, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice announces a sole source, firm fixed price contract awarded to CritiTech Particle Engineering Solutions, LLC by the Defense Health Agency. The contract is for the development of novel, super-critical precipitated drug products suitable for inhaled drug delivery to treat pulmonary infections. CritiTech was selected as the sole source provider due to their proprietary Purcision technology, which can produce drug particles of the required size, surface area, and without excipients to meet the government's specific needs. The 5-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract has an estimated total value of $709,995.75, with Firm Fixed Price task orders funded by the Defense Threat Reduction Agency.
Notice text
This contract was awarded sole source and firm fixed price to CritiTech
Particle Engineering Solutions, LLC due to their proprietary technology and
ability to meet the government's specific needs to delivery long-lasting
antimicrobials to the lungs would provide a novel, highly advantageous
medical countermeasure that would be easily deployable with the
Warfighter. CritiTech Particle Engineering Solutions, LLC is the sole
provider capable of developing novel, super-critical precipitated drug
products suitable for inhaled drug delivery for the treatment of pulmonary
infections. This vendor has a proprietary technology (Purcision) that relies
on supercritical precipitated API to produce particles in the correct size for
inhalation (0.5 – 5.0 μm) with very high surface area and no drug
excipients, which allows for high drug loads compared to other methods.
This vendor is the sole source of LSAM used for oncology programs and has
a demonstrated track record as a formulations contract research
organization (CRO). No other company found was able to deliver particles
that match all the requirements simultaneously.
Awarded contract HT9425-24-D-0011 to CRITITECH PARTICLE ENGINEERING SOLUTIONS, LLC for 709995.75 on 2024-09-06.
Files
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Award - Development of Novel Drug Particles for Inhalational Therapy | Award Notice | |
| Development of Novel Drug Particles for Inhalational Therapy | Special Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity